Patents Represented by Attorney, Agent or Law Firm A. D. Joran
-
Patent number: 6809094Abstract: The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant &agr;7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant &agr;7 nicotinic receptor agonist.Type: GrantFiled: August 28, 2002Date of Patent: October 26, 2004Assignee: Pfizer IncInventors: Brian Thomas O'Neill, Jotham Wadsworth Coe, Christopher J. O'Donnell
-
Patent number: 6794388Abstract: The present invention is directed to the succinate salts of 5,7,13-triazatetracyclo[9.3.1.02,10.04,8]-pentadeca-2(10),3,5,8-tetraene and pharmaceutical compositions thereof. The invention is also directed to a process for preparation of the succinate salts.Type: GrantFiled: November 27, 2002Date of Patent: September 21, 2004Assignee: Pfizer Inc.Inventors: George J. Quallich, Lewin T. Wint
-
Patent number: 6787549Abstract: The present invention is directed to the citrate salt of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene: and pharmaceutical compositions thereof. The present invention is also directed to the various forms of the citrate salt, particularly its hydrate and its anhydrous/nearly anhydrous polymorph. The invention is also directed to processes for preparation of these citrate salt forms.Type: GrantFiled: May 6, 2002Date of Patent: September 7, 2004Assignee: Pfizer Inc.Inventors: Phillip J. Johnson, Peter R. Rose, Glenn R. Williams, Lewin T. Wint
-
Patent number: 6677378Abstract: The present invention relates to compounds of the formula wherein R1 through R4, X, Y, m and n are defined as in the specification. Such compounds are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.Type: GrantFiled: April 30, 2001Date of Patent: January 13, 2004Assignee: Pfizer Inc.Inventors: Harry R. Howard, Jr., Christopher J. Schmidt, Thomas F. Seeger, Mark L. Elliott
-
Patent number: 6664258Abstract: This invention relates to novel, pharmaceutically active compounds of formula (I) wherein a, b and R1 through R6 are as defined in the specification These compounds exhibit central dopaminergic activity and are useful in the treatment of CNS disorders.Type: GrantFiled: February 24, 1999Date of Patent: December 16, 2003Assignee: Pfizer IncInventors: Anton F. J. Fliri, Todd W. Butler
-
Patent number: 6630467Abstract: Pyridone-fused azabicyclic compounds of the formula and their pharmaceutically acceptable salts and prodrugs, wherein R1, R2 and R3 are defined below, intermediates and methods for their preparation. Compositions and methods for using compounds of the formula I in the treatment of neurological and mental disorders related to a decrease in cholinergic function such as nicotine addiction, Huntington's Chorea, tardive dyskinesia, hyperkinesia, mania, dyslexia, schizophrenia, analgesia, attention deficit disorder (ADD), multi-infarct demetia, age related cognitive decline, epilepsy, neurological and mental disorders related to a decrease in cholinergic function, senile dementia of the Alzheimer's type, Parkinson's disease, attention deficit hyperactivity disorder (ADHD), anxiety, obesity, Tourette's Syndrome and ulcerative colitis.Type: GrantFiled: February 14, 2001Date of Patent: October 7, 2003Assignee: Pfizer Inc.Inventor: Brian T. O'Neill
-
Patent number: 6627627Abstract: The present invention relates to compounds of the formula wherein R1, R2, R3, X, Y and the dashed line are defined as in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. These compounds are useful as psychotherapeutic agents.Type: GrantFiled: November 6, 2001Date of Patent: September 30, 2003Assignee: Pfizer Inc.Inventor: Harry Ralph Howard
-
Patent number: 6608195Abstract: The present invention relates to a novel process for the preparation of a compound of formula I: wherein R1 is defined herein and compounds of formula II: wherein R1 and R2 are defined herein. Said compound of formula I is useful in the treatment of various central nervous system disorders including depression.Type: GrantFiled: August 29, 2002Date of Patent: August 19, 2003Assignee: Pfizer Inc.Inventors: Joseph P. Rainville, Terry G. Sinay, Stanley W. Walinsky
-
Patent number: 6605610Abstract: Compounds of the formula and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions containing such compounds; and methods of using such compounds in the treatment of neurological and psychological disorders.Type: GrantFiled: February 25, 2000Date of Patent: August 12, 2003Assignee: Pfizer IncInventors: Jotham Wadsworth Coe, Paige Roanne Palmer Brooks
-
Patent number: 6602874Abstract: A compound of the formula wherein X, Y, Z, R2 and R3 are as defined above, useful in treating or preventing migraine, depression and other disorders for which a 5-HT1, agonist or antagonist is indicated.Type: GrantFiled: May 22, 2001Date of Patent: August 5, 2003Assignee: Pfizer Inc.Inventor: Harry R. Howard
-
Patent number: 6596741Abstract: The present invention relates to compounds of formula I: and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.Type: GrantFiled: May 22, 2002Date of Patent: July 22, 2003Assignee: Pfizer IncInventors: Harry R. Howard, Mavis D. Adam
-
Patent number: 6579898Abstract: A composition comprising eletriptan and a p-glycoprotein (p-gp) inhibitor useful for the treatment of migraine. The bioavailability of eletriptan can be increased by co-administering eletriptan with a p-gp inhibitor. The eletriptan and p-gp inhibitor can be administered together in a composition or as separate components. If administered separately, they can be embodied as a kit. Also provided is a method of treating migraine using said composition or sequential administration of components.Type: GrantFiled: February 13, 2002Date of Patent: June 17, 2003Assignee: Pfizer Inc.Inventor: Michael John Humphrey
-
Patent number: 6562813Abstract: The present invention relates to compounds of the formula wherein R1, R2, R3, X, Y and the dashed line are defined as in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. These compounds are useful as psychotherapeutic agents.Type: GrantFiled: March 6, 2002Date of Patent: May 13, 2003Assignee: Pfizer Inc.Inventor: Harry Ralph Howard
-
Patent number: 6552015Abstract: The present invention is directed to a compound of the formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, Y, U, W, k, A, E, V, R4 and R5 are as defined herein, pharmaceutical compositions thereof, and methods of use thereof in the inhibition of serotonin reuptake, the inhibition of the binding of 5-HT2A serotonin receptors and the treatment of diseases, conditions or disorders of the central nervous system. Further, the present invention is also directed to methods for the preparation of compounds of formula (I) and intermediates useful therefor.Type: GrantFiled: August 1, 2001Date of Patent: April 22, 2003Assignee: Pfizer Inc.Inventors: Anton Franz Joseph Fliri, Todd William Butler, Randall James Gallaschun
-
Patent number: 6548502Abstract: The present invention provides a method of treating or preventing a novelty-seeking disorder, such as pathological gambling, attention deficit disorder with hyperactivity disorder and sex addiction, comprising administering a compound which is a dopamine D4 receptor ligand, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 26, 2001Date of Patent: April 15, 2003Assignee: Pfizer IncInventors: Stevin H. Zorn, Mark A. Sanner, Antor F. Fliri, Patricia A. Seymour
-
Patent number: 6537995Abstract: A method is provided for treating or preventing a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders, obesity, cluster headache, migraine, pain, obsessive-compulsive disorder, panic disorder, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, chronic paroxysmal hemicrania and headache in a mammal, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula (I) or the pharmaceutically acceptable salt thereof; wherein X, Y, Z, R2 and R3 are as defined herein.Type: GrantFiled: May 22, 2001Date of Patent: March 25, 2003Assignee: Pfizer Inc.Inventor: Harry R. Howard
-
Patent number: 6525196Abstract: The present invention relates to compounds of formula 1, wherein R1, R2, R3 and R4 are defined as in the specification. These compounds are useful as psychotherapeutic agents.Type: GrantFiled: December 6, 1999Date of Patent: February 25, 2003Assignee: Pfizer Inc.Inventors: Gene M. Bright, Kishor A. Desai
-
Patent number: 6525048Abstract: The present invention relates to compounds of the formula These compounds are useful as psychotherapeutic agents.Type: GrantFiled: January 18, 2000Date of Patent: February 25, 2003Assignee: Pfizer Inc.Inventor: Gene Michael Bright
-
Patent number: 6521630Abstract: The present invention relates to tetrahydroquinazoline-2,4-diones derivatives of the formula (I): pharmaceutically acceptable salts thereof, wherein A is (CH2)n where n is equal to 0, 1 or 2; U is CH2, NH, or NR3, R1 and R2 are selected independently from H, (C1-C6)alkyl, Cl, F, CN, nitro, CF3, —NHC(O)R6 and —OR7, or R1 and R2, together with the atoms to which they are attached, form a carbocyclic or heterocyclic five- or six-membered ring, R3 is selected from the group consisting of H, (C1-C6)malkyl, C(═O)—(C1-C6)alkyl, where m=1 or 2; R4 and R5 are selected from H, (C1-C6)alkyl, Cl, F, —CF3, —CN, —NHC(═O)R6, —OR7, a 5-to 7-membered aryl or heteroaryl ring, where m, R6 and R7 are as defined above; and R6 and R7 are selected independently from H, (C1-C6)alkyl or a 5- to 7-membered aryl or heteroaryl ring; V is CH, CR3, or N; W is CH2, C(O), or S(O)2; X is C or N; and Y is CH, CR1,CR2, or N.Type: GrantFiled: August 29, 2000Date of Patent: February 18, 2003Assignee: Pfizer Inc.Inventors: Anton Franz Joseph Fliri, Todd William Butler, Randall James Gallaschun, John Anthony Ragan, Brian Patrick Jones
-
Patent number: 6506780Abstract: This invention relates to a series of substituted benzophenone and sulfone compounds of the formula I wherein ring A, Z, Y, R and X are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.Type: GrantFiled: July 2, 2001Date of Patent: January 14, 2003Assignee: Pfizer Inc.Inventor: John A. Lowe, III